



**Date: 12<sup>th</sup> August, 2025**

To,  
Department of Corporate Services  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrip Code: 531569**

**Sub: Press Release on Unaudited Financial Results for the First Quarter ended June 30, 2025.**

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on Unaudited Financial Results for the First Quarter ended June 30, 2025.

Kindly take the above information on your records.

Thanking You,  
Yours Faithfully,

**For Sanjivani Paranteral Limited**

**Ravikumar Bogam**  
Company Secretary Cum Compliance Officer

## Press Release

### Sanjivani Paranteral Limited reported a strong performance for the quarter ended 30<sup>th</sup> June 2025

**Mumbai, 12<sup>th</sup> August 2025:** Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

**Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said,** “We are pleased to report a steady performance for Q1FY26, in the backdrop of challenges and uncertainties in the global trade environment. While the injectables segment reported strong growth, oral segment was impacted by shipment related challenges due to macro uncertainties. This will improve as we look into the coming quarters. Our commitment to long-term strategy remains unwavering. We are actively investing in R&D to expand our product portfolio. The continued performance of our export markets, which contributed significantly to our overall revenue, is a testament to this strategy. Despite the challenges posed by a dynamic global environment, our diversified portfolio and strategic focus should help us achieve significant revenue growth going ahead.”

#### Financial Summary:

##### **Q1 FY26:**

- Revenue from operations grew 8.9% YoY to Rs. 178.9 mn.
- EBITDA margin stood at 15.0% (up 26 bps YoY).
- Profit After Tax (PAT) stood at Rs. 17.3 mn. (up 1.0% YoY).

Particulars (Rs. in mn.)	Q1FY26	Q1FY25	Q4FY25
Total Income	179.3	165.2	186.1
Gross Profit	68.1	62.6	92.2
Gross Margin (%)	38.1%	38.1%	50.7%
EBITDA incl. other income	26.8	24.2	30.4
EBITDA Margin (%)	15.0%	14.7%	16.7%
PBT	23.0	22.7	26.5
PBT Margin %	12.8%	13.8%	14.3%
PAT	17.3	17.1	21.9
PAT Margin (%)	9.7%	10.4%	11.7%
Basic EPS (in INR)	1.46	1.47	1.84

**Segment-wise Performance:**

- **Injectables:** Revenue grew by 47.1% YoY to Rs. 89.9 mn.
- **Oral:** Revenue declined by 11.1% YoY to Rs. 88.2 mn.
- **Nutraceuticals:** Revenue stood at Rs. 0.8 mn in Q1FY26.

**Market-Wise Performance:**

- Exports (incl. Exports incentives) constitutes 73.7% of total revenue, while domestic constitutes the rest.
- Core markets of CIS (incl Russia), the Middle East & Africa and Latin America, accounted for 73.7% to Rs. 131.9 mn.

**Pritesh Jain**

Sanjivani Paranteral

Chief Financial Officer

[pritesh.jain@sanjivani.co.in](mailto:pritesh.jain@sanjivani.co.in)

---

**DISCLAIMER:**

*Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*